Recent Updates
Recently added Catalysts

PF-04236921

Phase 2

Crohn's Disease | Monoclonal antibody | Gastrointestinal |Pfizer, Inc.|Trials Updated: Jan 12, 2024

PF-04236921 development status

Highest phase Phase 2
Registered trials 3 across 1 sponsor since Jul 2010

PF-04236921 target and mechanism

ModalityMonoclonal antibody

Also known as PF-04236921 SC injection

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLEDDMC
Total Trials3
Total Enrollment624

FDA Designations

No designations recorded

PF-04236921 clinical trials

PF-04236921 · 3 trials · 2 indications

Phase 2 3
NCT01405196Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus ErythematosusLupus Erythematosus, Systemic
COMPLETED183 Analytics
NCT01345318B0151005 Open-Label Extension StudyCrohn's Disease
COMPLETED191 Analytics
NCT01287897A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF TherapyCrohn's Disease
COMPLETED250 Analytics
PHASE2COMPLETED
Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus
Lupus Erythematosus, SystemicUnlock trial analytics
PHASE2COMPLETED
B0151005 Open-Label Extension Study
Crohn's DiseaseUnlock trial analytics
PHASE2COMPLETED
A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy
Crohn's DiseaseUnlock trial analytics

Study Endpoints

Primary Endpoints

Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 24
Week 24

SRI components include:Systemic Lupus Erythematosus Disease Activity Index 2000(SLEDAI-2K),British Isles Lupus Assessment Group(BILAG) 2004,Physician's Global Assessment(PhGA).Participants classified as responder if they did not meet definition of treatment failure and met all the following criteria: greater than or equal to(\>=) 4 point reduction in SLEDAI-2K score; no new BILAG A organ domain score or 2 new BILAG B organ domain scores; no worsening (less than \[\<\] 0.3 point increase) in PhGA score. Treatment failure: any new/increased use of corticosteroids,immunosuppressants/antimalarial drug, any death, hospitalization/treatment discontinuation due to SLE, any flare of lupus interfering with participation in study. SLEDAI-2K:assesses improvement in disease activity (range: 0 to 105; higher score = higher severity). BILAG:assesses disease extent, severity (range: A\[severe\] to E\[no disease\]). PhGA: assesses worsening in participant's general health status(range: 0\[none\] to 3\[severe\]).

Number of Participants With On-Treatment Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), and Discontinuations Due to AEs
Baseline up to Week 48

An AE was any untoward medical occurrence without regard to causality in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of death); persistent or significant disability/incapacity; congenital anomaly. Lack of efficacy was reported as an AE when it was associated with a SAE. An AE was considered treatment emergent if it started for the first time in a participant on or after the first day of active treatment, or the event started before the first day of active treatment but increased in severity during active treatment. AEs included both SAEs and non-serious AEs.

Percentage of Participants Developing Anti-Drug Antibodies (ADAs) and Neutralizing Antibodies (NAbs)
At Baseline and Weeks 8, 16, 24, 32, 40, 48, 56, 64, 72 and 76.

Samples were analyzed using the semi-quantitative electrochemiluminescent (ECL) immunoassay method, a validated analytical method in compliance with sponsor's standard operating procedures. ADA positive is defined as ADA titer greater than or equal to (\>=) 4.32. Any positive ADA sample was further tested for NAbs.

The Crohn's Disease Activity Index (CDAI)-70 Response Rate at Week 8 in Participants Who Received Placebo, PF-04236921 10 mg and PF-04236921 50 mg
Baseline and Week 8

CDAI-70 response was defined as a decrease in CDAI score of 70 or greater from baseline. The proportions of participants with CDAI-70 response at Week 8 were compared between placebo and PF-04236921 10 mg/50 mg. CDAI is used to quantify the symptoms of patients with Crohn's Disease. CDAI evaluates 8 Crohn's disease-related variables during a 1-week assessment period, yielding a composite score greater than or equal to (\>=) 0 and without an upper limit. Many clinical trials use the endpoint for response as a 70 or greater point decrease in CDAI and clinical remission is often defined as a CDAI score below 150. The Outcome included a Generalized linear mixed model analyses which incorporated longitudinal data for each subject, and the same model is used for estimate (least squares mean) and statistical analysis (mean difference).

The CDAI-70 Response Rate at Week 8 in Participants Who Received Placebo and PF-04236921 200 mg
Baseline and Week 8

CDAI-70 response was defined as a decrease in CDAI score of 70 or greater from baseline. The proportions of participants with CDAI-70 response at Week 8 were compared between placebo and PF-04236921 200 mg. CDAI is used to quantify the symptoms of patients with Crohn's Disease. CDAI evaluates 8 Crohn's disease-related variables during a 1-week assessment period, yielding a composite score \>=0 and without an upper limit. Many clinical trials use the endpoint for response as a 70 or greater point decrease in CDAI and clinical remission is often defined as a CDAI score below 150. The Outcome included a Generalized linear mixed model analyses which incorporated longitudinal data for each subject, and the same model is used for estimate (least squares mean) and statistical analysis (mean difference). Since the inputs in the model included different Analysis Population than in Outcome Measure 1, that will yield different estimates for placebo for the two different models.

The CDAI-70 Response Rate at Week 12 in Participants Who Received Placebo, PF-04236921 10 mg and PF-04236921 50 mg
Baseline and Week 12

CDAI-70 response was defined as a decrease in CDAI score of 70 or greater from baseline. The proportions of participants with CDAI-70 response at Week 12 were compared between placebo and and PF-04236921 10 mg/50 mg. CDAI is used to quantify the symptoms of patients with Crohn's Disease. CDAI evaluates 8 Crohn's disease-related variables during a 1-week assessment period, yielding a composite score \>=0 and without an upper limit. Many clinical trials use the endpoint for response as a 70 or greater point decrease in CDAI and clinical remission is often defined as a CDAI score below 150. The Outcome included a Generalized linear mixed model analyses which incorporated longitudinal data for each subject, and the same model is used for estimate (least squares mean) and statistical analysis (mean difference).

The CDAI-70 Response Rate at Week 12 in Participants Who Received Placebo and PF-04236921 200 mg
Baseline and Week 12

CDAI-70 response was defined as a decrease in CDAI score of 70 or greater from baseline. The proportions of participants with CDAI-70 response at Week 12 were compared between placebo and PF-04236921 200 mg. CDAI is used to quantify the symptoms of patients with Crohn's Disease. CDAI evaluates 8 Crohn's disease-related variables during a 1-week assessment period, yielding a composite score \>=0 and without an upper limit. Many clinical trials use the endpoint for response as a 70 or greater point decrease in CDAI and clinical remission is often defined as a CDAI score below 150. The Outcome included a Generalized linear mixed model analyses which incorporated longitudinal data for each subject, and the same model is used for estimate (least squares mean) and statistical analysis (mean difference). Since the inputs in the model included different Analysis Population than in Outcome Measure 3, that will yield different estimates for placebo for the two different models.

Secondary Endpoints

Percentage of Participants Achieving Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 4, 8, 12, 16, and 20
Week 4, 8, 12, 16, 20
Percentage of Participants Achieving Modified Systemic Lupus Erythematosus (SLE) Responder Index (SRI) at Week 4, 8, 12, 16, 20, and 24
Week 4, 8, 12, 16, 20, 24
Percentage of Participants Achieving British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) Response at Week 4, 8, 12, 16, 20, and 24
Week 4, 8, 12, 16, 20, 24
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
10 mg of PF-04236921OTHER -
50 mg of PF-04236921OTHER -
200 mg of PF-04236921OTHER -
PlaceboOTHER -
Open-label TreatmentEXPERIMENTAL -
Placebo- SC injectionPLACEBO_COMPARATOR -
Drug Dose level 1 - SC injectionEXPERIMENTAL -
Drug Dose level 2 - SC injectionEXPERIMENTAL -

Interventions

NameTypeDescription
PF-04236921BIOLOGICALsubcutaneous injection; administered at day 1, weeks 8, 16.
PF-04236921 SC injectionDRUGPlacebo delivered SC, 2 doses separated by 4 weeks
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 75 Years
SexALL
Healthy VolunteersNo
Study Sites113

Inclusion Criteria: * Male or female subjects between ages of 18 and 75 years old at time of signing consent. * Have a clinical diagnosis of SLE according to 1997 update on the revised 1982 American College of Rheumatology (ACR) criteria. * Have a unequivocally positive anti-nuclear antibody (ANA) ...

Countries:United StatesArgentinaChileColombiaGermanyHungaryMoldovaPeruPolandPuerto RicoRomaniaSouth KoreaTaiwanAustraliaBelgiumBrazilCanadaCzechiaDenmarkFranceIrelandIsraelItalyNew ZealandSwitzerlandUnited KingdomGreece
Unlock Eligibility Criteria

Frequently asked questions about PF-04236921

What is PF-04236921 used for?

PF-04236921 is an investigational monoclonal antibody that has been studied in Phase 2 clinical trials for Crohn's disease and systemic lupus erythematosus. It was evaluated in patients with Crohn's disease who had failed anti-TNF therapy, as well as in adults with generalized lupus erythematosus.

Who is developing PF-04236921?

PF-04236921 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 2 clinical trials of the drug in Crohn's disease and systemic lupus erythematosus.

What phase is PF-04236921 in?

PF-04236921 is in Phase 2 development. Two Phase 2 trials have been completed, and there are currently no active trials. The drug is investigational and has not been approved by the FDA for any indication.

What clinical trials is PF-04236921 in?

PF-04236921 has been studied in three completed Phase 2 trials: NCT01287897 in Crohn's disease patients who failed anti-TNF therapy, NCT01345318 an open-label extension study in Crohn's disease, and NCT01405196 in systemic lupus erythematosus. All trials were randomized, double-blind, and placebo-controlled.

Is PF-04236921 the same as PF-04236921 SC injection?

Yes, PF-04236921 SC injection is another name for PF-04236921. The SC designation refers to subcutaneous administration, which was the route used in the clinical trials of the drug.